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Neuroendocrine tumors (NETs) are often diagnosed from the metastases of an unknown primary tumor. Specific
immunohistochemical (IHC) markers indicating the location of a primary tumor are needed. The proprotein convertase
subtilisin/kexin type 2 (PCSK2) is found in normal neural and neuroendocrine cells, and known to express in NETs.
We investigated the tissue microarray (TMA) of 86 primary tumors from 13 different organs and 9 metastatic NETs,
including primary tumor-metastasis pairs, for PCSK2 expression with polymer-based IHC. PCSK2 was strongly posi-
tive in all small intestine and appendiceal NETs, the so-called midgut NETs, in most pheochromocytomas and para-
gangliomas, and in some of the typical and atypical pulmonary carcinoid tumors. NETs showing strong positivity were
re-evaluated in larger tumor cohorts confirming the primary observation. In the metastases, the expression of PCSK2
mirrored that of the corresponding primary tumors. We found negative or weak staining in NETs from the thymus,
gastric mucosa, pancreas, rectum, thyroid, and parathyroid. PCSK2 expression did not correlate with Ki-67 in well-dif-
ferentiated NETs. Our data suggest that PCSK2 positivity can indicate the location of the primary tumor. Thus,
PCSK2 could function in the IHC panel determined from screening metastatic NET biopsies of unknown primary ori-
gins.
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The incidence of rare tumors of neuroendocrine ori-
gin is increasing (1). Hormone-producing neuroen-
docrine tumors (NETs) can occur anywhere in the
body because NETs arise from dispersed or aggre-
gated neuroendocrine (NE) cells. NE cells are
found in the bronchus, the gastrointestinal (GI)
tract, the islets of Langerhans of the pancreas, the
thyroid (as C cells), and the skin (as Merkel cells)
(2). Pheochromocytomas (PHEOs) arise from the
adrenal medulla, while paragangliomas (PGLs)
arise from sympathetic or parasympathetic para-
ganglions (3). The most common NET sites are the
GI tract and the lungs, while other locations such
as the genitourinary tract and breast, are extremely
rare (4). A general histological feature of neuroen-
docrine neoplasia that differentiates them fromReceived 4 March 2020. Accepted 29 June 2020
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adenocarcinomas is the presence of cytoplasmic
endocrine granules, a key feature of neuroendocrine
specialization. Various hormones produced by
NETs are stored in NE-specific granules (5). Rec-
ommended immunohistochemical (IHC) markers
for the diagnosis of NETs are chromogranin A
(CGA) and synaptophysin (SYP), the so-called
common NE markers (6).
While radiological and nuclear imaging constitute
first-line methods to diagnosing, staging, and the
surveillance of NETs (7), primary tumors can be
very small and undetectable upon imaging. Because
the clinical presentation of NETs is often indolent,
the diagnosis of malignant NETs is frequently
made from a metastatic tumor sample. Knowledge
of the primary tumor origin carries meaningful
therapeutic significance to applying of adequate
surgical and medical management, since the
response to various treatments varies according to
NET origin (8). In the Surveillance, Epidemiology,
and End Results (SEER) 18 registry, the incidence
of NETs with an unknown primary origin reached
0.84 per 100 000 population (1). The common NE
markers CGA and SYP can indicate the NE nature
of a metastatic tumor, but are uninformative
regarding the tumor’s location. Thus, organ-specific
IHC markers play an important role in determining
the tumor origin from tissue samples of an
unknown primary tumor (9). For the diagnosis of
metastatic NETs with an unknown origin, a proper
antibody panel indicating the primary NET loca-
tion is needed (10). Many organ-specific markers
are proteins naturally occurring in specific cell
types. Therefore, markers such as thyroid transcrip-
tion factor-1 (TTF-1) indicating a lung and thyroid
origin (10–12), caudal type homeobox 2 (CDX2)
indicating a GI origin (10,12,13), and insulin gene
enhancer-binding protein islet-1 (ISL1) and paired
box 8 (PAX-8) indicating NETs of a pancreatic ori-
gin (14) have served to suggest the primary tumor
location. New NE markers are identified from time
to time (15). Antibodies are used in panels, since
relying on a single primary antibody is never ade-
quately specific or sensitive (16).
The proprotein convertase subtilisin/kexin type 2
(PCSK2) gene is located on chromosome 20, band
p11.2 (17). The PCSK2 enzyme, a member of the
serine protease family, is synthesized in the endo-
plasmic reticulum as inactive prePCSK2. Moving
toward secretory granules, the prePCSK2 is prote-
olytically activated within the acidic compartments
of the secretory pathway (18). PCSK2 is expressed
in various neuroendocrine cell lines (19) and NE
cells (20, 21). In NE cells, PCSK2 is a principal
mediator of prohormones and propeptides (18, 21–
23). Reports by Scopsi et al. 1995 (20), Kajiwara
et al. 1999 (24), Kimura et al. 2000 (25), and
Tomita et al. 2001 (26) have described PCSK2
expression in human NE tissues and NETs (20, 24–
27). The presence of the enzyme in NETs has been
identified using various methods: IHC (20, 24–26),
immunoblotting (20), electron microscopy (20), and
mRNA in situ hybridization (24). PCSK2 has also
been studied in adenocarcinomas (28).
Here, we aimed to investigate the expression
levels and distribution of PCSK2 by relying on a
normal NE cells, on a cohort of 86 primary tumors
originating from 13 different organs, and in 9 meta-
static NETs, and evaluate the usefulness of PCSK2
as a candidate for inclusion on a NET antibody
panel. Strongly PCSK2 expressing NETs were
investigated more precisely in larger tumor cohorts.
MATERIAL AND METHODS
Tumor material and normal neuroendocrine cell
material
The study protocol adhered to the Helsinki Declaration of
1975 and was approved by the Ethics Committee of Hel-
sinki University Hospital (3990/04/046/07). All of the
methods followed the relevant guidelines and regulations.
Tumor material was collected from the archives of the
Department of Pathology, Helsinki University Hospital. The
tumor series consisted of 95 neuroendocrine tumors, consist-
ing of primary (n = 86) and metastatic (n = 9) tumors of var-
ious grades from different organs (29). Histopathological
diagnoses were re-evaluated from hematoxylin-eosin stained
slides by an experienced endocrine pathologist J.A. (Fig. 1).
Further analysis of the PCSK2 expression was performed on
32 PHEOs and 4 PGLs, as well as 20 small intestine and 38
pulmonary NETs. Adenocarcinomas from the pancreas
(n = 27), gastric mucosa (n = 49) and colon (n = 24) served
as parallel tumor material.
Normal NE tissue material (the bronchus, gastric
mucosa, pancreas, small intestine, colorectum, thyroid,
and adrenal medulla) was dissected from surgical patient
materials. Both tumor and normal tissue materials were
fixed in 10% formalin for 24–72 h, followed by normal
laboratory processes (tissue processing, microtomy cutting,
and hematoxylin-eosin stain) and interpretation by a
pathologist.
Tissue microarray blocks
Tissue microarray (TMA) blocks of multi-NETs, PHEOs,
and PGLs, as well as adenocarcinomas of the pancreas,
gastric mucosa, and colon were previously constructed;
three parallel blocks with 1-mm double-punch cores were
taken from the tumor area with a semiautomated TMA
instrument (Beecher Instruments, Silver Spring, MD,
USA). Pulmonary carcinoid TMA blocks were constructed
with TMA Grandmaster (3DHistech, Budapest, Hungary)
covering 1-mm double punches from the middle of the
tumor, the tumor border, outside of the tumor, and from
the bronchus, resulting in at total of seven punches per
sample.
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Immunohistochemistry
Tumor material was stained for PCSK2, chromogranin A,
Ki-67, and serotonin. The slides were pretreated with the
following reagents: (i) for PCSK2 (polyclonal,
HPA048851,Sigma-Aldrich, St. Louis, MO, USA) and
chromogranin A (polyclonal, A0430, Agilent, Santa Clara,
CA, USA) in a pretreatment module (LabVision UK Ltd.,
UK) with a citrate buffer at pH 6.0; (ii) for Ki-67 in a
microwave oven with Tris-EDTA at pH 9.0 (clone MIB-1,
M7240, Agilent, Santa Clara, CA, USA); and (iii) sero-
tonin (clone 5HT-H209, M0758, Agilent, Santa Clara,
CA, USA) was stained without pretreatment. Endogenic
peroxidase was blocked with the Dako REAL Peroxidase-
Blocking Solution (Agilent, Santa Clara, CA, USA), and
the antigens were visualized with the EnVisionTM HRP
conjugated polymer detection kit (Agilent, Santa Clara,
CA, USA) in a LabVision Autostainer 480 (Thermo Sci-
entific, Fremont CA, USA). PCSK2 (1:500), chromo-
granin A (1:2000), Ki-67 (1:100), and serotonin (1:10)
were incubated for 30 min at room temperature. The
slides were counterstained with Mayer’s hematoxylin (Lil-
lie’s Modification) (Agilent, Santa Clara, CA, USA) and
mounted with Eukitt quick-hardening mounting medium
(Sigma-Aldrich, St. Louis, MO, USA).
Adjustment of the IHC protocol for PCSK2 (30, 31)
and evaluation of the primary antibody specificity was
based on a literature review of the enzyme location in
normal NE tissues and NE cell components (5, 20, 21). In
the accepted IHC setting, the enzyme was expressed in the
expected histological (NE cells, islet of Langerhans) and
cellular (cytoplasmic) locations (32). Nonspecific back-
ground staining or staining of the cell component assumed
to be negative for the antibody used was not accepted (33,
34). Control tissues (small intestine and pancreas) were
present in every IHC staining replicate as a patch-control
slide. Stromal cell components (lymphocytes, fibroblasts)
served as the internal negative controls (33, 34).
Western blot analysis
The PHEO tumor was taken from deep-freeze (70 °C)
in the Department of Pathology, Helsinki University
Hospital. The tissue was homogenized and lysed with an
LSB-buffer (Bio-Rad, Hercules, CA, USA). Samples were
titrated as 2, 5, and 10 µL, and subjected to 10% SDS-
PAGE and immunoblotted onto an Immobilon-FL
Transfer Membrane (Merck Millipore, Burlington, MA,
USA). Blots were incubated overnight at +4 °C with
polyclonal PCSK2 (HPA048851, Sigma-Aldrich, St.
Louis, MO, USA) at a dilution of 1:1000 followed by
Alexa Fluor 680-conjugated secondary goat anti-rabbit
antibody (1:10 000) and enhanced with the Odyssey (LI-
COR Biosciences, Lincoln, NE, USA) chemiluminescence
detection.
A B
C D
Fig. 1. Representative hematoxylin-eosin stainings of the PHEO (A), PGL (B), pulmonary carcinoid (C), and small intes-
tine NET (D). Objective: 409.
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Scoring
PCSK2 was scored for cytoplasmic positivity as follows:
0 = none, 1 = mild, 2 = moderate, and 3 = strong (Fig. 2).
For further analysis, 0 and 1 were considered negative,
while 2 and 3 were considered positive. Staining for multi-
NETs, PHEOs and PGLs was evaluated independently by
S.R. and H.L., and those for the pulmonary carcinoids
were evaluated by S.R. and T.V. The highest consensus
score was selected for statistical analysis.
The Ki-67 proliferation index (35, 36) was assessed
using the image analysis software ImmunoRatio
(jvsmicroscope.uta.fi/immunoratio/) for all multi-NET
TMAs and the whole-slide small intestine NETs (37).
Positivity for chromogranin A confirmed the neuroen-
docrine nature of the NETs . Serotonin staining was inter-
preted as positive or negative (Fig. 2).
Statistical analysis
We used the Fisher’s exact test in the statistical analyses
and considered p < 0.001 as statistically significant. Statis-
tical analyses were performed using the SPSS 17.0 soft-
ware program (SPSS Inc., Chicago, IL, USA).
A B
C D
E F
Fig. 2. Immunohistochemical expression of PCSK2 in the NETs from the rectum (A), pancreas (B), PHEO (C), and small
intestine (D). Scoring intensities for PCSK2 from 0–1 (A, B), and 2–3 (C, D) with the representative tumor areas. Sero-
tonin expression in the NETs scored as negative (E, pulmonary) or positive (F, small intestine). Objective: 409.
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RESULTS
The characterization of PCSK2 antibody
The specificity of the PCSK2 antibody was moni-
tored using Western blot analysis on fresh frozen
PHEO tumor tissue. In crude extracts from the
tumor material, titrated as 2, 5, and 10 µL, PCSK2
revealed a clear band migrating at an expected size
of 70 565 Da (Fig. 3).
PCSK2 expression in normal tissue
The NE cells of the small intestine and the adrenal
medulla were strongly positive for PCSK2. The NE
cells of the gastric mucosa, bronchus, islets of
Langerhans, and thyroid C cells also stained posi-
tively, but at a lower intensity. Parietal cells of the
gastric mucosa were also positive for PCSK2. We
found no positivity in the NE cells of the colon
mucosa (Fig. 4).
PCSK2 expression in neuroendocrine tumors
PCSK2 was positive in all midgut NETs (small
intestine and appendix; 12/12), in half of the typical
and atypical lung carcinoids (4/8) and pituitary ade-
nomas (2/4), and in none of the rectal NETs (0/5).
The PHEOs (4/5) and PGLs (3/5) stained strongly.
None of the NETs from the thymus, gastric
mucosa, pancreas, thyroid, and parathyroid glands
exhibited PCSK2 expression or showed a weak
expression, which we considered negative (Table 1).
Furthermore, PCSK2 positivity did not correlate
with the Ki-67 proliferation index in any well-differ-
entiated NET. PCSK2 expression associated with
the serotonin expression in the small intestine NETs
(p < 0.001).
Because of the strong PCSK2 expression in the
small intestine NETs, pulmonary NETs, PHEOs,
and PGLs, the correctness of the staining was stud-
ied further using larger tumor cohorts. The results
were concordant with those of the original multi-
NET TMA. Small intestine NETs (20/20) expressed
PCSK2 across the entire tumor area. Among the
pulmonary NETs, half of the typical (13/19) and
atypical lung carcinoids (9/19) were positive. In the
majority of PHEOs, both non-metastatic (22/29)
and metastatic (2/3) as well as PGLs (3/4) all
stained strongly (Table 2).
PCSK2 expression in neuroendocrine metastases
Table 3 summarizes the PCSK2 expression in pri-
mary tumor-metastases pairs. Most of the meta-
static tumors showed comparable PCSK2
expression to the primary tumors.
PCSK2 in adenocarcinomas
PCSK2 staining was negative in 27 pancreatic and
49 gastric adenocarcinomas. Colon carcinomas
showed a focal cytoplasmic positivity in 33% of
cases, as summarized in Table 4.
DISCUSSION
We found strong positivity for PCSK2 in midgut
NETs, PHEOs, and PGLs. Half of the typical and
atypical pulmonary carcinoids were also strongly
positive, yet NETs from other organs were negative.
The staining patterns and intensities were similar in
primary tumors and their corresponding metastases.
PCSK2 expression did not correlate with the prolif-
eration index of well-differentiated tumors.
PCSK2 localizes in the granules of NE cells (5).
Our findings showed a strong cytoplasmic positivity
in appendiceal and small intestine NETs—the so-
called midgut NETs—which agrees with previous
reports (20, 24, 25, 26). The majority of PHEOs
and PGLs, and half of the lung carcinoids and
pituitary adenomas, were positive for PCSK2, sup-
porting earlier observations of PCSK2 positivity in
NETs (20, 24, 27). NETs originating from the thy-
mus, gastric mucosa, pancreas, and colorectum
were negative for PCSK2. Yet, our findings on
PCSK2 expression in foregut and hindgut NETs
differed from previous reports (20, 24, 25, 26).
Fig. 3. Western blot analysis of the specificity of the
PCSK2 antibody using PHEO in 2 µL (A), 5 µL (B), and
10 µL (C). Antibody selectively detects the correct protein
at the expected level without cross-reaction with other
proteins in the tissue extract. About 10% of the empty
margins of the original gel photograph are cropped. The
picture is rotated three degrees CCV. The contrast levels
are those obtained by the gel scanner.
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Interestingly, Kajiwara et al. 1999 (24) described
weak or negative mRNA (in situ hybridization)
levels for PCSK2 in hindgut NETs, mirroring our
IHC results. We found no positivity in thyroid
medullary carcinomas, unlike reports from Scopsi
et al. 1995 (20) and Kajiwara et al. 1999 (24). How-
ever, parathyroid adenomas and carcinomas were
negative as previously indicated by Scopsi et al.
1995 (20). Table 5 summarizes the staining of
PCSK2 in different studies.
Partial differences in the staining results may be
explained by differences in the technical details and
the selection of tumor material. The IHC staining
results vary according to the choice of antigen
retrieval methods, detection kits and selected anti-
bodies (38). Previous studies used biotin as the
reactive molecule for color production (20, 24, 25,
26) together with a high-temperature antigen retrie-
val (20, 26). Advances in the polymer detection
technology allow for sensitive detection without the
A B C D
E F G H
I J
M N
K L
Fig. 4. The expression of chromogranin A (A, C, E, G, I, M), calcitonin (K) and PCSK2 (B, D, F, H, J, L, N) in normal
tissue NE cells from the bronchus (A, B), gastric mucosa (C, D), pancreas (E, F), small intestine (G, H), colorectum (I, J),
thyroid C cells (K, L), and adrenal medulla (M, N). Objective: 209. The insert shows the bronchial NE cells; objective:
409.
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associated problems characteristic of endogenous
biotin (39, 40). The selection of primary antibody
plays a central role in IHC. All of the studies with
PCSK2 rely on polyclonal primary antibodies (20,
24, 25, 26). The staining results using polyclonal
antibodies are partly tied to the batch-to-batch
variation of the antibody production and the purifi-
cation steps (31). In addition, the antibody’s ability
Table 1. PCSK2 expression in NETs from 13 different organs
Tumor location Organ Diagnosis (n) Gender (M:F) Ki-67 (Range) PCSK2 (POS)
Foregut Pulmonary Typical carcinoid (n = 6) 1:5 1.4–3.4% 3 (50%)
Atypical carcinoid (n = 2) 2:0 4.1–5.8% 1 (50%)
Large cell neuroendocrine
carcinoma (n = 2)
0:2 63.6–77.6% 0%
Small cell lung carcinoma (n = 4) 1:3 61.6–97.5% 0%
Thymus Well-differentiated neuroendocrine
carcinoma (n = 1)
0:1 5.1% 0%
Gastric mucosa NET G2 (n = 3) 2:1 5.8–18.9% 0%
NEC G3 (n = 3) 2:1 64.6–97.4% 0%
Pancreas NET G1 (n = 3) 0:3 0.8–1.3% 0%
NET G2 (n = 7) 3:4 2.1–13.7% 0%
NEC G3 (n = 1) 1:0 69.6% 0%
Midgut Appendix NET G1 (n = 4) 1:3 1.0–1.6% 4 (100%)
NET G2 (n = 2) 0:2 3.5–4.0% 2 (100%)
Small intestine NET G1 (n = 3) 3:0 1.1–1.9% 3 (100%)
NET G2 (n = 3) 1:2 2.3–11.3% 3 (100%)
Hindgut Rectum NET G2 (n = 4) 0:4 2.1–9.6% 0%
NEC G3 (n = 1) 1:0 79.9% 0%
Other Thyroid Medullary thyroid carcinoma (n = 5) 2:3 1.1–8.0% 0%
Parathyroid Parathyroid carcinoma (n = 2) 1:1 2.1–2.6% 0%
Parathyroid adenoma (n = 3) 0:3 0.4–2.0% 0%
Adrenal medulla Pheochromocytoma (n = 5) 3:2 1.4–3.7% 4 (80%)
Paraganglia Paraganglioma (n = 5) 2:3 2.0–3.6% 3 (60%)
Skin Merkell cell carcinoma (n = 4) 3:1 38.3–89.2% 1 (25%)
Pituitary Adenoma (n = 4) 4:0 1.0–1.8% 2 (50%)
Total n = 77 n = 26
Table 2. PCSK2 expression in large cohorts of the small intestine, pulmonary, adrenal, and extra-adrenal NE tumors
Tumor location Diagnosis (n) Gender (M:F) Ki-67 (Range) PCSK2 (POS)
Small intestine NET G1 (n = 13)
NET G2 (n = 7)
4:9
4:3
0.3–1.8%
2.1–3.6%
13 (100%)
7 (100%)
Pheochromocytoma Non-metastatic (n = 29) 11:18 0.0–8.0% 22 (76%)
Metastatic (n = 3) 3:0 3.0–10.0% 2 (66%)
Paraganglia Non-metastatic (n = 0) 0:0 - -
Metastatic (n = 4) 3:1 1.0–8.0% 3 (75%)
Pulmonary Typical carcinoid (n = 19)
Atypical carcinoid (n = 19)
10:9
8:12
<1.0–8.0%
<1.0–10.0%
13 (68%)
9 (47%)
Total n = 94 n = 69
Table 3. PCSK2 expression in primary tumor-metastases pairs
Primary tumor location Metastases
PSCK2 Expression 0–1 + (NEG) 2–3 + (POS)
Pulmonary
(n = 5)
Typical carcinoid (n = 2)
Atypical carcinoid (n = 3)
2–3 + (POS) 1 Typical carcinoid (n = 1) 4 Typical carcinoid (n = 1)
Atypical carcinoid (n = 3)
Pulmonary
(n = 6)
Typical carcinoid (n = 2)
Atypical carcinoid (n = 4)
0–1 + (NEG) 4 Typical carcinoid (n = 1)
Atypical carcinoid (n = 3)
2 Typical carcinoid (n = 1)
Atypical carcinoid (n = 1)
Small intestine
(n = 1)
2-3 + (POS) 0 1
Pancreas (n = 4) 0-1 + (NEG) 4 0
Total n = 16 n = 9 n = 7
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to recognize the target antigen depends on the pep-
tide fragments used for immunization. The poly-
clonal primary antibody represents a mixture of
different antibodies recognizing different epitopes of
the target protein (40). Thus, the polyclonal anti-
body is a good choice for recognizing antigens with
low expression levels, heterogeneity, or post-transla-
tional modifications (31). In our study, we used
commercially produced PCSK2 with standardized
production and purification steps. Furthermore, the
binding specificity of the PCSK2 antibody to the
target protein was confirmed using Western blot
analysis. The antibody used by Scopsi et al. 1995
(20) was raised against a peptide fragment corre-
sponding to the prePCSK2 variant of the enzyme.
All of these methodological differences may explain
the incoherencies we detected between results.
Because PCSK2 is known to process hormones in
NE cells (21), the selection of the tumor material
may affect the overall staining. In our NET mate-
rial, we were blinded to the NET hormonal activity,
particularly in pancreatic NETs, which have mostly
been hormonally active in other studies (20, 25).
Tissue markers suitable for the detection of
tumors of unknown origin must be stable. Lineage-
specific transcription factors, such as CDX2 and
TTF-1, are considered highly specific and sensitive
markers capable of indicating a tumor’s GI and
pulmonary origin (11–13), respectively. PCSK2 rep-
resents an integral part of the dense-core granules
found naturally in NE cells (5, 20). In our NET
material, the intensity and expression profile of
PCSK2 was similar in the primary tumors (pul-
monary, pancreas, and small intestine) and the cor-
responding metastases (liver, lymph node, pleura,
and soft tissue). All pancreatic and gastric adeno-
carcinomas were negative for PCSK2 although
colon carcinomas showed a focal positivity, as pre-
viously established (28). In the diagnosis of
unknown primary tumors, PCSK2 appears suitable
for indicating a tumor’s NE nature. If PCSK2 is
used in an antibody panel, it appears to indicate
the primary tumor location, particularly those with
a midgut, pulmonary, or pheochromocytoma-para-
ganglion origin. However, the clinical value and
usefulness of PCSK2 requires further examination.
The proliferation index specifies the NET grades
(35, 36). Well-differentiated and poorly differentiated
NETs differ in their expression profile for IHC
markers (6, 10). It seems that PCSK2 is a stable
antigen independent of the grade. In our tumor
material, PCSK2 did not correlate with Ki-67, sup-
porting an earlier observation (27). Similarly, the
percentage of typical and atypical PCSK2-positive
carcinoids remained rather uniform, further indicat-
ing that proliferation does not correlate with PCSK2
expression. These results suggest that PCSK2 may
be a valuable addition to an IHC panel as a grade-
independent marker of NETs, at least in well-differ-
entiated NE tumors with a proliferation of 1–20%.
The staining pattern of PCSK2 was cytoplasmic,
with a polarization and occasional granules. In
small intestine NETs, pulmonary NETs, PHEOs,
and PGLs, PCSK2 polarization was seen in single
cells or in peripheral tumor areas. NETs secrete
Table 4. PCSK2 expression in adenocarcinomas
Adenocarcinomas (n) PCSK2
0–1 + (NEG)
PCSK2
2–3 + (POS)
Pancreas (n = 27) 100% (n = 27) –
Gastric (n = 49) 100% (n = 49) –
Colon (n = 36) 66.6% (n = 24) 33.3% (n = 12)
Total n = 112 n = 100 n = 12
Table 5. PCSK2 staining in parallel studies
References Lung/bronchus
A) Typical
B) Atypical
Thymus Gastric
mucosa
Pancreas Appendix Small
intestine
Colorectal Thyroid Parathyroid
A) Adenoma
B) Carcinoma
Pheochromocytoma Paraganglioma
Scopsi et al.
1995 (20)
n = 123
6/71 – 4/8 11/11 2/2 6/6 3/6 9/9 A) 0/7
B) –
6/6 6/6
Kajiwara
et al. 1999
(24)
n = 26
7/91 – 2/4 – – – 2/4 1/1 A) 3/4
B) –
2/2 –
Kimura et al.
2000 (25)
n = 61
– 2/2 1/7 10/16 – 2/2 6/29 – – – –
Tomita et al.
2001 (26)
n = 35
– – 3/3 – 7/7 11/11 10/10 – – – –
Present study
n = 164
A) 16/25
B) 10/22
0/1 0/6 0/11 6/6 26/26 0/5 0/5 A) 3/4
B) –
28/37 6/9
1No definition of the classification used.
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various hormones, and PCSK2 is part of the hor-
mone maturation process (21–23). Most likely, the
amount and biological variation in the hormone
production and processing explains the variation in
the staining intensity seen in our normal NE cell
tissues and the NET cohort.
The proprotein convertase family is a nine-mem-
ber protein family whose substrates are well-known
cancer-associated proteins containing a cleavage site
for proprotein convertases. The strong polarity of
PCSK2 toward the stromal component in small
intestine NETs may indicate some role in tumor
invasion. Further studies are, however, needed since
IHC only indicates the location of proteins, but
cannot indicate their function.
A few limitations to our study should be noted.
The use of TMA tissue material may compromise
some of the PCSK2 positivity if the enzyme
expression varies. We used parallel tissue cords to
minimize this effect (41, 42), although interesting
observations of PCSK2 positivity in tumors
included in the TMA screening were further con-
firmed using larger tumor cohorts. As a method,
IHC is not quantitative, and the semi-quantitative
evaluation of IHC can be reliable only with care-
fully validated and standardized IHC protocol set-
tings. The need for standardization should be
realized when new, potential markers are dis-
cussed.
In conclusion, our results indicate that PCSK2 is
a potential diagnostic marker for identifying NETs
from the small intestine, appendix, and lung, as
well as PHEOs and PGLs. PCSK2 did not correlate
with Ki-67 and showed no loss of IHC reactivity in
metastatic tumors, suggesting an antigenic stability
in tumor differentiation. Like many IHC markers,
PCSK2 was not completely specific for NETs.
However, if added to an antibody panel, PCSK2
immunoreactivity could contribute to defining the
NE nature and origin of unknown primary NETs.
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